Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
AssigneeAlcon Manufacturing, Ltd.
InventorsMark R. Hellberg, Jon C. Nixon
Life of this patent
Estimating the term…
Abstract
Disclosed are methods and compositions for the treatment of glaucoma and ocular hypertension, comprising the administration of a prostaglandin FP receptor agonist and a prostaglandin synthesis inhibitor.
Claims4
A method of treating glaucoma, comprising administering to an affected eye a combination of an intraocular pressure lowering effective amount of a prostaglandin FP receptor agonist, and a prostaglandin synthesis inhibiting effective amount of a prostaglandin synthesis inhibitor other than diclofenac or fluorometholone.
A topical ophthalmic composition comprising an intraocular pressure lowering effective amount of a prostaglandin FP receptor agonist selected from the group consisting of latanoprost, travoprost, and bimatoprost;
- a prostaglandin synthesis inhibiting effective amount of nepafenac;
- and an ophthalmically acceptable vehicle therefore.
Dependencies are inferred from the claim text.